Format

Send to

Choose Destination
Curr Opin Chem Biol. 2002 Aug;6(4):472-8.

Progress toward the development of agents to modulate the cell cycle.

Author information

1
Pfizer Global Research and Development 2800 Plymouth Road, Ann Arbor, MI 48105, USA. peter.toogood2@pfizer.com

Abstract

With taxanes continuing to prove useful in the clinical treatment of cancer, the next generation of antimitotic agents has entered clinical trials. Other mechanisms awaiting proof-of-concept for the treatment of antiproliferative diseases include inhibition of cyclin-dependent kinases (Cdks). Flavopiridol and UCN-01 are continuing in clinical trials, and newer more selective Cdk inhibitors are now entering clinical evaluation.

PMID:
12133723
DOI:
10.1016/s1367-5931(02)00342-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center